University of Minnesota
516 Delaware St. SE
Minneapolis, MN 55455
United States
University of Minnesota is one of seventeen type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Antoinette Moran, MD, the TrialNet team at University of Minnesota is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Our Team
Antoinette Moran, MD
Brandon Nathan, MD
Shannon Beasley, NP
Jose Jimenez-Vega, MD
Jacob Kohlenberg, MD
Beth Pappenfus
Janice Leschyshyn, RN
Kali Johnson, MPH
Study Coordinator
Veronica Jones-Carr, RN
Regional Affiliates
Research Studies
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
TrialNet tested a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it could delay or prevent type 1 diabetes (T1D) in people ages 6 to 34 who had a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk was defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More
TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details
TrialNet conducted a Phase 1 study to test the safety and dosing of a new plasmid immunotherapy for the first time in people. Earlier studies in the lab showed this immunotherapy might be able to teach the immune system to stop its attack on insulin-producing beta cells. More
